CA AB2989

Exempts from state sales and use taxes the gross receipts from sales of reagents, chemicals, lab equipment, and supplies used by licensed blood banks to perform FDA-mandated screening tests on donated human blood, effective January 1, 2021 through December 31, 2022.

Defines "blood screening tests" to include tests for ABO/Rh typing, antibodies, syphilis, hepatitis B and C, HIV, HTLV, Chagas disease, West Nile virus, Zika virus, and any future FDA-required donor screening tests.

Requires the Central California Blood Center and Stanford Blood Center to annually report to the California Department of Tax and Fee Administration on the number of blood banks initiating in-facility testing and whether new testing facilities are established in California.

States that the state shall not reimburse local agencies for sales and use tax revenue losses resulting from this exemption, notwithstanding existing reimbursement requirements.

Takes effect immediately as a tax levy.